Ionis Pharmaceuticals, Inc. vs ImmunityBio, Inc.: Strategic Focus on R&D Spending

Ionis vs. ImmunityBio: A Decade of R&D Investment

__timestampImmunityBio, Inc.Ionis Pharmaceuticals, Inc.
Wednesday, January 1, 20141595000241751000
Thursday, January 1, 201511434000322292000
Friday, January 1, 201626546000344320000
Sunday, January 1, 201739778000374644000
Monday, January 1, 201853418000414604000
Tuesday, January 1, 2019111997000466000000
Wednesday, January 1, 2020139507000535000000
Friday, January 1, 2021195958000643000000
Saturday, January 1, 2022248149000833000000
Sunday, January 1, 2023232366000899625000
Loading chart...

Unlocking the unknown

A Decade of R&D Investment: Ionis Pharmaceuticals vs. ImmunityBio

In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Ionis Pharmaceuticals, Inc. and ImmunityBio, Inc. have demonstrated contrasting strategies in their R&D investments.

From 2014 to 2023, Ionis Pharmaceuticals consistently outpaced ImmunityBio in R&D spending, with an average annual investment nearly five times greater. Notably, Ionis's R&D expenses surged by approximately 272% from 2014 to 2023, peaking at nearly $900 million in 2023. In contrast, ImmunityBio's R&D spending grew by an impressive 14,500% over the same period, reflecting its aggressive push into the biotech arena.

This strategic focus on R&D underscores the companies' dedication to pioneering new therapies and maintaining a competitive edge in the rapidly evolving pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025